Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05044728|
Recruitment Status : Recruiting
First Posted : September 16, 2021
Last Update Posted : September 16, 2021
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer Esophageal Squamous Cell Carcinoma||Drug: Anti-PD-1 antibody combined with Paclitaxel and carboplatin. Procedure: Surgical treatment stage||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This study is a prospective, single-arm, open cohort study (randomly stratified within the group).|
|Masking:||None (Open Label)|
|Official Title:||The Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumor of the Chest.|
|Actual Study Start Date :||April 1, 2021|
|Estimated Primary Completion Date :||April 1, 2022|
|Estimated Study Completion Date :||March 31, 2023|
Experimental: Neoadjuvant Chemotherapy Immunotherapy stage
Patients with locally advanced non-small cell lung cancer and locally advanced thoracic esophageal squamous cell carcinoma who met the entry and discharge criteria will be enrolled. After detecting the functional subsets of peripheral CD8-positive T cells, the group was randomly stratified 1:1, respectively. Group A received immunotherapy 24 hours after chemotherapy, and group B received chemotherapy 24 hours after immunotherapy.
Drug: Anti-PD-1 antibody combined with Paclitaxel and carboplatin.
Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.
Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy.
Procedure: Surgical treatment stage
After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
- Functional subsets of peripheral CD8 positive T cells [ Time Frame: Approximately 1 years ]
- Overall response rate(ORR) [ Time Frame: Approximately 1 years ]Objective Response Rate is defined as complete response (CR) + partial response (PR), from the beginning of regimental therapy to the end of neoadjuvant therapy, the efficacy of baseline target lesions was assessed by RECIST 1.1 criteria.
- Pathological complete response (pCR) [ Time Frame: At time of surgery ]Pathological complete response is defined as 0% survival of tumor cells in surgically resected tumor samples after neoadjuvant therapy, as assessed by tumor regression grade.
- Immune Related Adverse Events (irAEs) [ Time Frame: Approximately 1 years ]Assess all adverse events according to the NCI Common Terminology Criteria for (NCI-CTCAE) v 4.0.3.
- Progress Free Survival(PFS) [ Time Frame: Approximately 1 years ]Progress Free Survival is defined as included the development of new metastases, or local progression of metastases or primary lesions that underwent surgical resection and will be assessed according to RESIST 1.1 criteria.
- 2-year survival rate [ Time Frame: up to 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05044728
|Contact: Qiang Fang, PH.Demail@example.com|
|Sichuan Cancer Hospital||Recruiting|
|Chengdu, Sichuan, China, 610000|
|Contact: Qiang Fang +8618980758305 firstname.lastname@example.org|
|Principal Investigator:||Qiang Fang, PH.D||Sichuan Cancer Hospital and Research Institute|